{"id":61880,"date":"2025-09-17T13:03:52","date_gmt":"2025-09-17T11:03:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/"},"modified":"2025-09-17T13:03:52","modified_gmt":"2025-09-17T11:03:52","slug":"nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/","title":{"rendered":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<b><i>In a new publication, bioengineered multimodal nanofilaments <\/i><i>uncloak cancer cells and recruit both innate and adaptive <\/i><i>immune systems to eradicate tumors<\/i><\/b><\/p>\n<p>SHERBROOKE, Qu\u00e9bec&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/JITC?src=hash\" target=\"_blank\">#JITC<\/a>&#8211;TATUM bioscience, a preclinical biotechnology company developing a new immunotherapy to fight cancer, announced the publication of new research showing strong antitumor activity from its proprietary bioengineered multimodal nanofilaments. The study, published in the new issue of the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjitc.bmj.com%2Fcontent%2F13%2F8%2Fe011331&amp;esheet=54325621&amp;newsitemid=20250917616133&amp;lan=en-US&amp;anchor=Journal+for+Immunotherapy+of+Cancer&amp;index=1&amp;md5=3039bff375a617dd61722f72bd7ce1c6\" rel=\"nofollow\" shape=\"rect\">Journal for Immunotherapy of Cancer<\/a> (JITC), details how this groundbreaking therapy exposes (\u201cuncloaks\u201d) cancer cells and orchestrates a comprehensive immune response that eradicates tumors.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/5\/Logo_2022.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/5\/Logo_2022.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/21\/Logo_2022.jpg\"><\/a><\/p>\n<p>\n\u201cOur innovative nanofilament-directed immunotherapy overcomes cancer\u2019s ability to hide from the immune system and unleashes a coordinated immune response against tumor cells,\u201d said Jean-Fran\u00e7ois Millau, Ph.D., co-founder and Chief Executive Officer of TATUM Bioscience.<\/p>\n<p>\n\u201cThe immune system can be compared to an orchestra: for a powerful antitumor response, each instrument \u2014 or cellular component \u2014 must play its part at the right moment. That\u2019s what our drug candidate, TAT003, achieves.\u201d Dr. Millau is a co-author on the article, \u201c<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fjitc.bmj.com%2Fcontent%2F13%2F8%2Fe011331&amp;esheet=54325621&amp;newsitemid=20250917616133&amp;lan=en-US&amp;anchor=Nanofilament+immunotherapy+induces+potent+antitumor+vaccine+responses&amp;index=2&amp;md5=efbb5946888eb01fca3d4088ae8817d4\" rel=\"nofollow\" shape=\"rect\">Nanofilament immunotherapy induces potent antitumor vaccine responses<\/a>.\u201d<\/p>\n<p>\n<b>How TAT003 Works<\/b><\/p>\n<p>\nTAT003 is administered directly into the tumor (\u201cintratumorally\u201d) and combines three biological functions to drive the immune system\u2019s antitumor response:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Checkpoint Blockade: <\/b>Anti\u2013PD-L1 single-chain antibody fragments at one end of the nanofilament bind to tumor cells, decorating the tumor and blocking the PD-L1 immune checkpoint. This allows the immune system to recognize and target the cancer.<\/li>\n<li>\n<b>Innate Activation:<\/b> Encapsulated within the nanofilament is a TLR9 agonist, which activates macrophages to engulf tumor cells. Activated macrophages present tumor antigens to the broader immune system.<\/li>\n<li>\n<b>T Cell Stimulation:<\/b> IL-2 molecules on the nanofilaments stimulate T cells, triggering them to seek out and destroy other cells bearing tumor antigens \u2014 mimicking a vaccine-like response.<\/li>\n<\/ul>\n<p>\n\u201cStrikingly, the antitumor response triggered by TAT003 nanofilament immunotherapy was both systemic and durable in animal models,\u201d said Kevin Neil, Ph.D., co-founder and Chief Scientific Officer of TATUM. \u201cReplicating these results in patients is our goal as we move toward clinical development.\u201d<\/p>\n<p>\n<b>Unique Advantages Over Personalized Vaccines<\/b><\/p>\n<p>\nTATUM\u2019s engineered nanofilaments offer distinct advantages over other therapeutic strategies. According to Dr. Neil, \u201cTAT003 elicits a vaccine-like effect without the complexity and cost of individualized neoantigen vaccines, which require tumor sequencing and custom manufacturing for each patient. Our approach is designed to be more practical and scalable.\u201d<\/p>\n<p>\nManufacturing complex, multi-specific biologics remains a major challenge in biopharma. TAT003 addresses this with a proprietary synthetic biology platform: \u201cWe have engineered bacteria to function as miniature drug factories, producing fully assembled therapeutic nanofilaments in a single step,\u201d explained Dr. Millau. \u201cWe simply culture the bacteria, and they secrete the complete, functional drug.\u201d<\/p>\n<p>\nDr. Gerald Batist, director of the Segal Cancer Centre at Jewish General Hospital in Montr\u00e9al, commented, \u201cThese results are highly promising and suggest that nanofilament-directed immunotherapy could overcome some of the limitations seen with today\u2019s personalized neoantigen approaches. Engaging both innate and adaptive immunity, as shown here, is likely key to improving outcomes for patients who do not benefit from current immunotherapies. This represents a major step forward in the evolving landscape of immuno-oncology.\u201d Dr. Batist is a medical advisor to TATUM.<\/p>\n<p>\n<b>Looking Ahead<\/b><\/p>\n<p>\nThese findings represent a major milestone for TATUM Bioscience and the advancement of nanofilament-directed immunotherapy, paving the way for a powerful and innovative approach to treating solid tumors. TATUM is currently raising funds to accelerate development and bring TAT003 into clinical trials. The company welcomes interest from investors, partners, and clinicians seeking to be part of this next era in cancer immunotherapy.<\/p>\n<p>\n<b><span class=\"bwuline\">About TATUM bioscience<\/span><\/b><\/p>\n<p>\nTATUM bioscience is a privately held preclinical biotechnology company in Sherbrooke, Qu\u00e9bec, Canada, advancing next-generation immunotherapies to treat life-altering diseases including cancer. The company produces multimodal bioengineered nanofilaments using a proprietary synthetic biology platform. The nanofilament-directed immunotherapy demonstrates effective tumor clearance activity, low side-effect profiles, and durable responses. To learn more, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tatumbio.com%2F&amp;esheet=54325621&amp;newsitemid=20250917616133&amp;lan=en-US&amp;anchor=TATUM+bioscience&amp;index=3&amp;md5=b3845b1c39ad68b7845d7735626b702a\" rel=\"nofollow\" shape=\"rect\">TATUM bioscience<\/a> website.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>TATUM BIOSCIENCES Media Contact:<\/b><br \/>Jeffrey Krasner<br \/>\n<br \/><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fsloweymcmanus.com%2F&amp;esheet=54325621&amp;newsitemid=20250917616133&amp;lan=en-US&amp;anchor=Slowey+McManus+Communications&amp;index=4&amp;md5=a29b72965c567ec965e760f21fb23ecc\" rel=\"nofollow\" shape=\"rect\">Slowey McManus Communications<\/a><br \/><a target=\"_blank\" href=\"mailto&#58;&#106;&#107;&#114;&#97;&#115;&#110;&#x65;&#x72;&#x40;&#x73;&#x6c;&#x6f;&#x77;&#x65;&#x79;&#x6d;&#x63;&#x6d;anus&#46;c&#111;&#109;\" rel=\"nofollow\" shape=\"rect\">&#x6a;&#x6b;&#x72;&#x61;&#x73;&#x6e;&#x65;&#x72;&#x40;&#x73;&#x6c;&#111;&#119;&#101;&#121;&#109;&#99;&#109;anus&#46;c&#x6f;&#x6d;<\/a><br \/>+1-617-840-9806<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In a new publication, bioengineered multimodal nanofilaments uncloak cancer cells and recruit both innate and adaptive immune systems to eradicate tumors SHERBROOKE, Qu\u00e9bec&#8211;(BUSINESS WIRE)&#8211;#JITC&#8211;TATUM bioscience, a preclinical biotechnology company developing a new immunotherapy to fight cancer, announced the publication of new research showing strong antitumor activity from its proprietary bioengineered multimodal nanofilaments. The study, published &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61880","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"In a new publication, bioengineered multimodal nanofilaments uncloak cancer cells and recruit both innate and adaptive immune systems to eradicate tumors SHERBROOKE, Qu\u00e9bec&#8211;(BUSINESS WIRE)&#8211;#JITC&#8211;TATUM bioscience, a preclinical biotechnology company developing a new immunotherapy to fight cancer, announced the publication of new research showing strong antitumor activity from its proprietary bioengineered multimodal nanofilaments. The study, published ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T11:03:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors\",\"datePublished\":\"2025-09-17T11:03:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250917616133\\\/en\\\/2582864\\\/22\\\/Logo_2022.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/\",\"name\":\"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250917616133\\\/en\\\/2582864\\\/22\\\/Logo_2022.jpg\",\"datePublished\":\"2025-09-17T11:03:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250917616133\\\/en\\\/2582864\\\/22\\\/Logo_2022.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250917616133\\\/en\\\/2582864\\\/22\\\/Logo_2022.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend","og_description":"In a new publication, bioengineered multimodal nanofilaments uncloak cancer cells and recruit both innate and adaptive immune systems to eradicate tumors SHERBROOKE, Qu\u00e9bec&#8211;(BUSINESS WIRE)&#8211;#JITC&#8211;TATUM bioscience, a preclinical biotechnology company developing a new immunotherapy to fight cancer, announced the publication of new research showing strong antitumor activity from its proprietary bioengineered multimodal nanofilaments. The study, published ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-17T11:03:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors","datePublished":"2025-09-17T11:03:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/"},"wordCount":674,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/","url":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/","name":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg","datePublished":"2025-09-17T11:03:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250917616133\/en\/2582864\/22\/Logo_2022.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanofilament-directed-immunotherapy-shows-promising-results-in-treating-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nanofilament-directed Immunotherapy Shows Promising Results in Treating Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61880"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61880\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}